RecruitingPHASE1, PHASE2NCT06501625
Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Studying Cholangiocarcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Institut de Recherches Internationales Servier
- Intervention
- Ivosidenib(drug)
- Enrollment
- 52 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2027
Study locations (30)
- Usc Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Northwestern Medicine, Chicago, Illinois, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Duke University, Durham, North Carolina, United States
- Gibbs Cancer Center, Spartanburg, South Carolina, United States
- Tennesse Oncology - Elliston Place Plaza, Nashville, Tennessee, United States
- The University of Texas Md Anderson Cancer Center, Houston, Texas, United States
- Alfred Health, Melbourne, Australia
- Hospital de Amor - Barretos, Barretos, Brazil
- Oncoclinicas Mg, Belo Horizonte, Brazil
- CIONC, Curitiba, Brazil
- Instituto Dor de Pesquisa E Ensino Sp, São Paulo, Brazil
- Princess Margaret Cancer Centre, Toronto, Canada
- Institut Bergonie, Bordeaux, France
- Hôpital Beaujon, Clichy, France
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06501625 on ClinicalTrials.govOther trials for Cholangiocarcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07478523FAPI-PET Value for the Initial Screening of Pancreatic and Biliary CancersUniversity Hospital, Bordeaux
- RECRUITINGNANCT07476651Scout Dose of Resin MicrospheresSeoul National University Hospital
- RECRUITINGPHASE2NCT06728410A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or RearrangementMehmet Akce
- RECRUITINGPHASE2NCT07201519Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion ChemotherapyMichael J Cavnar, MD
- RECRUITINGPHASE2NCT07223307REGULUS: MRI-guided Adaptive SABR for Liver CancersStanford University
- RECRUITINGPHASE2NCT07260175Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 CholangiocarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- RECRUITINGNANCT06735560Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NENNantes University Hospital
- RECRUITINGNANCT07263217Mechanistic Study on the Protective and Regenerative Effects of Spirulina in Hepatectomy-Related Liver InjurySecond Affiliated Hospital, School of Medicine, Zhejiang University